Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-009 + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT03657420Phase 1Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- May 2019
- Primary completion
- Sep 2021
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nab-sirolimus in multiple myeloma (MM), sponsored by Massachusetts General Hospital. Primary endpoint: Maximum Tolerated Dose. Planned start May 2019; status: withdrawn.
02
Drugs
nab-sirolimus
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03657420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03657420.